Research Topics
Species | Jms BartlettSummaryAffiliation: University of Edinburgh Country: UK Publications
| Collaborators
|
Detail Information
Publications
Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinomaDana Faratian
Division of Pathology and Endocrine Cancer Group, University of Edinburgh Cancer Research Centre, Edinburgh, UK
Histopathology 54:254-7. 2009..The aim was to describe the pattern and frequency of membranous/cytoplasmic Ki67 in a cohort of invasive breast carcinomas, and their associations with grade, HER2 amplification and oestrogen receptor (ER) expression...
Relative impact of key sources of systematic noise in Affymetrix and Illumina gene-expression microarray experimentsRobert R Kitchen
Applied Bioinformatics of Cancer Group, Breakthrough Breast Cancer Research Unit, Institute of Genetics and Molecular Medicine, Crewe Road South, Edinburgh, Edinburgh, EH4 2XR, UK
BMC Genomics 12:589. 2011....- Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancerSampoorna Satheesha
Leeds Institute of Molecular Medicine, St, James s University Hospital, Leeds University, UK
Mol Cancer 10:19. 2011..In an alternative approach we estimated eIF4E activity, a key effector of mTOR function, and tested the hypothesis that eIF4E activity predicts sensitivity to mTOR inhibition in cell lines and in breast tumours... - Correcting for intra-experiment variation in Illumina BeadChip data is necessary to generate robust gene-expression profilesRobert R Kitchen
School of Physics, University of Edinburgh, 10 Crichton Street, Edinburgh, EH8 9AB, UK
BMC Genomics 11:134. 2010.... - External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot schemeJohn M S Bartlett
Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK
J Clin Pathol 60:816-9. 2007..Background and.. - Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)John M S Bartlett
Endocrine Cancer Group, Edinburgh University, Edinburgh, UK
Lancet Oncol 11:266-74. 2010..We investigated prospectively predictive biomarkers of anthracycline benefit including HER2 and TOP2A... - A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: intersite variation can be rigorously controlled using FISHJohn M S Bartlett
Endocrine Cancer Group, Edinburgh University Cancer Research Centre, Western General Hospital, Edinburgh, UK
Histopathology 56:297-304. 2010..To assess a new HER2 fluorescence in situ hybridization (FISH) test and report on multicentre intrasite and intersite variation... 
Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancerM Spears
Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XR, Scotland
Biomark Med 2:397-407. 2008..Here we review the human epidermal growth factor receptor family of proteins and their potential predictive or prognostic role in early breast cancer...- Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapyJohn M S Bartlett
Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh University, Carrington Crescent, Edinburgh EH4 2XU, UK
Breast Cancer Res 12:R47. 2010..We tested the efficacy of this panel in a mixed population of cases treated in a single center with breast-conserving surgery and long-term follow-up... - Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trialJohn M S Bartlett
Endocrine Cancer Research Group, Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK
J Clin Oncol 26:5027-35. 2008..We tested the hypothesis that HER2, epidermal growth factor receptor (EGFr)/HER1, HER3, Ki67, and topoisomerase IIalpha expression are predictive of outcome after anthracycline-based chemotherapy... - Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directionsJohn M S Bartlett
Endocrine Cancer Group and Edinburgh Breakthrough Breast Cancer Laboratory, Edinburgh University, Western General Hospital, Crewe Road South, Edinburgh, UK
Clin Breast Cancer 10:S86-95. 2010..Herein, gaps in current knowledge are highlighted and suggestions for future research directions given that may facilitate biomarker development in partnership with current drug development... - Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trialJohn M S Bartlett
Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Rd South, Edinburgh, EH4 2XR, United Kingdom
J Clin Oncol 29:1531-8. 2011.... - Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapyJohn M S Bartlett
Endocrine Cancer Research Group, Edinburgh University Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom
J Clin Oncol 25:4423-30. 2007..We tested interactions between ER and HER-2 to determine if they may modulate breast cancer nodal metastasis and proliferation... - Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?Sian Tovey
Endocrine Cancer Group, Section of Surgical and Translational Research, Glasgow University, United Kingdom
Clin Cancer Res 11:4835-42. 2005..We previously reported reduced survival in patients overexpressing HER1, HER2, and HER3. We now show that both HER1-3 and PR status predicts for early relapse in estrogen receptor (ER)-positive tamoxifen-treated breast cancer patients... - Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancerVicky S Sabine
Endocrine Cancer Group, University of Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XR, UK
Breast Cancer Res Treat 122:419-28. 2010.... - Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labellingSian M Tovey
Endocrine Cancer Group, Division of Cancer Sciences and Molecular Biology, University Department of Surgery, Glasgow Royal Infirmary, Glasgow G31 2ER, UK
Breast Cancer Res 6:R246-51. 2004..In this study, bromodeoxyuridine (BrdU)-derived proliferation indices are correlated with clinical outcome and HER1-4 status for further clarification of the differing roles for the HER family at a biological level... - Bad expression predicts outcome in patients treated with tamoxifenElizabeth Cannings
Endocrine Cancer Group, Glasgow Royal Infirmary, University Department of Surgery, Glasgow, Scotland, UK
Breast Cancer Res Treat 102:173-9. 2007..The present study was carried out to test the hypothesis that disruption of apoptosis in breast cancer, via Akt activation, is linked with hormone resistance... - Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patientsTove Kirkegaard
Endocrine Cancer Group, Section of Surgical and Translational Research, Glasgow University, Glasgow Royal Infirmary, Glasgow, United Kingdom
Clin Cancer Res 13:1405-11. 2007..The present study was carried out to test the hypothesis that AIB1 protein expression and/or gene amplification mediates tamoxifen resistance in breast cancer... - AKT activation predicts outcome in breast cancer patients treated with tamoxifenTove Kirkegaard
Endocrine Cancer Group, Division of Cancer Sciences and Molecular Pathology, Department of Surgery, Glasgow Royal Infirmary, Glasgow G31 2ER, UK
J Pathol 207:139-46. 2005.... - Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM Trial ExperienceDana Faratian
Division of Pathology, Edinburgh Cancer Research Centre, Edinburgh, Scotland
Histopathology 55:587-93. 2009..The aim of this study was to investigate the potential of image analysis for accurate and reproducible quantitative evaluation of biomarkers... - The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancerJoanne Edwards
Endocrine Cancer Group, Division of Cancer Sciences and Molecular Pathology, Glasgow Royal Infirmary, Glasgow, United Kingdom
Clin Cancer Res 12:123-30. 2006..Breast cancer studies show that these receptors should be investigated as a family. The current study investigates expression of HER1-HER4 and EGFRvIII in matched hormone-sensitive and hormone-refractory prostate tumors... - Hormonal therapy for postmenopausal breast cancer: the science of sequencingWilliam R Miller
Breast Unit, Western General Hospital, Paderewski Building, Edinburgh, EH4 2XU, UK
Breast Cancer Res Treat 103:149-60. 2007..Prospective, randomized clinical trials are needed to determine the best use of therapies in particular settings, taking into account the spectrum of molecular phenotypes in different tumours... - HER2 FISH in breast cancerJohn M S Bartlett
Division of Cancer and Molecular Pathology, University Department of Surgery, Glasgow Royal Infirmary, Scotland, UK
Methods Mol Med 97:89-101. 2004 - Pharmacodiagnostic testing in breast cancer: focus on HER2 and trastuzumab therapyJohn M S Bartlett
Section of Surgical and Translational Research, Division of Cancer, Department of Surgery, Sciences and Molecular Pathology, Endocrine Cancer Group, Glasgow Royal Infirmary, University of Glasgow, Glasgow, Scotland
Am J Pharmacogenomics 5:303-15. 2005..This approach serves as a paradigm for the future development of pharmacodiagnostic tests in oncology... - Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?John M S Bartlett
Endocrine Cancer Group, Edinburgh University Cancer Research Centre, Western General Hospital, Edinburgh, Scotland, UK
Am J Clin Pathol 130:920-6. 2008..We recommend that all breast cancer cases with a HER2 copy number of 2 to 7 determined by single-color in situ hybridization should also be analyzed for chromosome 17 to obtain a more accurate diagnosis of HER2 amplification... - Expression of tumor necrosis factor alpha converting enzyme in endocrine cancersTove Kirkegaard
Endocrine Cancer Research Group, Division of Cancer Sciences and Molecular Pathology, University Department of Surgery, Glasgow Royal Infirmary, Glasgow, Scotland
Am J Clin Pathol 129:735-43. 2008..The data presented herein show TACE expression in endocrine cancers and further support a role for TACE in breast cancer apoptosis... - HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4Sian M Tovey
Endocrine Cancer Group, Section of Surgical and Translational Research, Glasgow University, UK
Breast Cancer Res 8:R19. 2006..We have therefore compared the staining patterns of antibodies against its intracellular and extracellular domains using tissue microarray technology... - Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patientsLiane M McGlynn
Endocrine Cancer Group, Division of Cancer Studies and Molecular Pathology, University Department of Surgery, Glasgow Royal Infirmary, Glasgow, United Kingdom
Clin Cancer Res 15:1487-95. 2009.... - Human epidermal growth factor receptor dimerization analysis in breast cancer diagnosis: potential for improving testing accuracy and treatment selectionMelanie Spears
Edinburgh Breakthrough Breast Cancer Research Unit, Endocrine Cancer Research Group, Western General Hospital, Edinburgh, UK
Mol Diagn Ther 13:359-65. 2009..Here, we review the methods by which HER dimerization can be explored and the potential that this has in the treatment of breast cancer... - Histological grading of invasive breast carcinoma--a simplification of existing methods in a large conservation series with long-term follow-upJeremy St J Thomas
Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK
Histopathology 55:724-31. 2009.... - The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathwaysJoanne Edwards
Section of Surgical and Translational Research, Division of Cancer and Molecular Pathology, University Department of Surgery, Glasgow Royal Infirmary, Glasgow, Scotland, UK
BJU Int 95:1327-35. 2005 - External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance schemeJohn M S Bartlett
Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, Scotland
Am J Clin Pathol 131:106-11. 2009..Participation in external quality assurance schemes is a valuable mechanism for demonstrating and acquiring consistency for HER2 testing by in situ hybridization. Poor performance can be corrected via assistance and advice... - The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptorJoanne Edwards
Section of Surgical and Translational Research, Division of Cancer and Molecular Pathology, University Department of Surgery, Glasgow Royal Infirmary, Glasgow, Scotland, UK
BJU Int 95:1320-6. 2005 - The role of c-Jun and c-Fos expression in androgen-independent prostate cancerJoanne Edwards
Endocrine Cancer Group, Section of Surgical and Translational Research, University of Glasgow, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK
J Pathol 204:153-8. 2004..However, PKC appears to promote the development of AIPC independently of c-Jun activation via an as yet unexplained mechanism... - Fluorescence in situ hybridization: technical overviewJohn M S Bartlett
Division of Cancer and Molecular Pathology, University Department of Surgery, Glasgow Royal Infirmary, Scotland, UK
Methods Mol Med 97:77-87. 2004 - Gene amplifications associated with the development of hormone-resistant prostate cancerJoanne Edwards
University of Glasgow, Glasgow, United Kingdom
Clin Cancer Res 9:5271-81. 2003..Hormone resistance remains a significant clinical problem in prostate cancer with few therapeutic options. Research into mechanisms of hormone resistance is essential... - A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissuePauline J Carder
Department of Histopathology, St. James's University Hospital, Leeds, UK
Breast Cancer Res Treat 92:287-93. 2005..Our results emphasise the need for further studies addressing the role of ERb to be based on a wider consensus on criteria for positivity. Ideally this should be based on calibration against clinical outcome... - Type I receptor tyrosine kinases are associated with hormone escape in prostate cancerJohn M S Bartlett
Division of Cancer Sciences and Molecular Pathology, University Department of Surgery, Level II Queen Elizabeth Building, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK
J Pathol 205:522-9. 2005.... - Expression of the HER1-4 family of receptor tyrosine kinases in breast cancerCaroline J Witton
University Department of Surgery, Glasgow Royal Infirmary, Glasgow G31 2ER, UK
J Pathol 200:290-7. 2003..The development of HER-targeted agents (eg Herceptin, Iressa), and agents targeted at the downstream signalling pathways, therefore provides new possibilities in the treatment of breast cancer... - Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridizationJorma Isola
Laboratory of Cancer Genetics, Institute of Medical Technology, University and University Hospital of Tampere, Tampere, Finland
Clin Cancer Res 10:4793-8. 2004..CONCLUSIONS: These results indicate that CISH could provide an accurate and practical alternative to FISH for clinical diagnosis of HER-2/neu oncogene amplification in archival formalin-fixed breast cancer samples... - Detection of HER2 gene amplification by fluorescence in situ hybridization in breast cancerJohn M S Bartlett
Division of Cancer Sciences and Molecular Pathology, University Department of Surgery, Endocrine Cancer Group and HER2 Reference Laboratory, University of Glasgow, Glasgow Royal Infirmary, UK
Methods Mol Med 120:309-22. 2006..We describe the use of FISH for HER2 in our own laboratory, based on more than 4000 diagnostic assays, and the optimal approaches to scoring HER2 gene amplification in breast cancer... - Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladderJoanne Edwards
University Department of Surgery, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK
J Pathol 196:380-5. 2002..Loss of all informative markers, including those residing in the TSC1 region, spanning chromosome 9 was also linked to recurrence... - The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cellsAnjali Naresh
Department of Biochemistry, Tulane University Health Sciences Center, Tulane Cancer Center, LA 70112 2699, USA
Cancer Res 66:6412-20. 2006..Thus, we propose that ligand-induced mitochondrial accumulation of 4ICD represents a unique mechanism of action for transmembrane receptors, directly coupling a cell surface signal to the tumor cell mitochondrial apoptotic pathway... - An increase in N-Ras expression is associated with development of hormone refractory prostate cancer in a subset of patientsPamela Traynor
University Department of Surgery, Division of Cancer Sciences and Molecular Pathology, Glasgow Royal Infirmary, Glasgow, UK
Dis Markers 24:157-65. 2008..010) and proliferation index (Ki67, p=0.02). These results suggest that in a subgroup patients N-Ras expression is associated with development of hormone refractory prostate cancer via activation of the MAP kinase cascade...